FDA-approved eye drops target presbyopia patients

Cathleen McCabe, MD, discusses VUITY, the first and only FDA-approved eye drop to treat age-related blurry near vision, and how it provides opportunities for patients looking for spectacle independence.

The relationship between myopia and conjunctival-scleral geometry

Nasotemporal sagittal height asymmetry a good biomarker of shortsightednes.

Highlighting results from first FDA-reported study for treatment of presbyopia

George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial (by Allergan, an Abbvie company) of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.